NeuroPace (NPCE) Announces Two Management Appointments

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Katie Keller as the new Vice President of Marketing, effective immediately.

“We are excited to welcome Katie and Brett to our team. Katie brings an understanding of the neurostimulation market and expertise in market development through her tenure at Boston Scientific and leading its DBS commercial marketing function. I’m confident that through her leadership our market development programs and plans will move to the next level as we look to close the treatment gap by driving broader adoption and utilization of RNS therapy,” said Joel Becker, Chief Executive Officer of NeuroPace. “Brett is a proven innovator and developer of advanced medical devices, which includes our RNS technology. His extensive knowledge of the RNS System and epilepsy will position him to help advance our strategy to expand the capabilities of the RNS System through our technology development plans and pipeline.”

“I am excited to join NeuroPace and look forward to working with the team on expanding access to the Company’s life changing RNS therapy through indication expansion and increased awareness with both patients and clinicians,” stated Ms. Keller.

Ms. Keller brings significant experience and a track record of success in medical device marketing and commercial roles to NeuroPace. Most recently, she led the global commercial marketing function for Boston Scientific’s Neuromodulation Deep Brain Stimulation (DBS) franchise. In addition, she brings deep experience in marketing and market development from her leadership roles with a number of device markets, including Interventional Cardiology, Cardiac Physiology and Cardiac Rhythm Management. Ms. Keller received a Masters in Bioscience (MBA/Bioengineering hybrid program) from the Keck Graduate Institute and a Bachelor of Science degree in Biomedical Engineering from the University of Southern California.

“I am excited to rejoin NeuroPace at such an exciting time for the Company and for the RNS System,” said Dr. Wingeier. “The unique monitoring and analysis capabilities of the RNS System have provided us with an unparalleled dataset. I look forward to working with the team and our customers to further evolve these capabilities and translate these data into enhanced ease of use, greater efficiency, and clinical insights that continue to transform the lives of people living with epilepsy.”

Brett brings more than 20 years of experience across neurotech, biomedical engineering and entrepreneurship to the Company, including more than a decade as a key contributor to the development of NeuroPace’s RNS System in the early 2000s. Most recently, Dr. Wingeier served as CEO, CTO and co-founder of Magnus Medical, gaining FDA clearance for a data-driven, individually targeted hardware and software platform with rapid effectiveness in major depression. Prior to Magnus, he served as the CTO, CEO and co-founder of Halo Neuroscience, a venture-backed company focusing on non-invasive neuromodulation for human performance, from 2013 to 2019. Prior to Halo, Dr. Wingeier served as a Principal Engineer at NeuroPace from 2001 to 2013, during which time he was instrumental in projects including development of the RNS System and analysis of the Company’s earliest clinical data. He holds a Bachelor of Science in Engineering and Ph.D. in Biomedical Engineering from Tulane University. Dr. Wingeier is a U.S. registered patent agent with more than 70 issued patents.

You May Also Be Interested In

• Correction: Kepler Cheuvreux Upgrades Siemens AG (SIE:GR) (SIEGY) to Hold
• Meta's Zuckerberg Says Ai Agent Tech Progressing Slower Than Expected - Reuters
• Trifecta Gold closes $1.66M private placement for Yukon exploration